<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558580</url>
  </required_header>
  <id_info>
    <org_study_id>E2080-A001-301</org_study_id>
    <nct_id>NCT04558580</nct_id>
  </id_info>
  <brief_title>Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency&#xD;
      in subjects with partial seizures not fully controlled despite treatment with 1 to 3&#xD;
      concomitant antiepileptic drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total partial seizure frequency from baseline.</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Refractory Partial Seizures</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rufinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rufinamide</intervention_name>
    <description>Rufinamide</description>
    <arm_group_label>Rufinamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female patients between 12 and 80 years of age&#xD;
&#xD;
          -  Dx of epilepsy with partial onset seizures woth or woth out secondarily generalized&#xD;
             seizures&#xD;
&#xD;
          -  Non controlled partial seizures despite treatment with 2 different AEDs for at least 2&#xD;
             years&#xD;
&#xD;
          -  must have 6 seizures during baseline&#xD;
&#xD;
          -  current treatment with maximum of 3 AEDs&#xD;
&#xD;
          -  stable dose of AED(s)for at least 1 month&#xD;
&#xD;
          -  if patient has VNS, must have been implanted 6 months prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any investigational product for at least 1 month prior to visit 1&#xD;
&#xD;
          -  Presence of non-motor simple partial seizures only&#xD;
&#xD;
          -  presence of generalized epilepsies&#xD;
&#xD;
          -  Evidence of clinically significant disease&#xD;
&#xD;
          -  Clinically significant ECG&#xD;
&#xD;
          -  Psychogenic seizure in previous year&#xD;
&#xD;
          -  History of drug/alcohol abuse&#xD;
&#xD;
          -  History of suicide attempt&#xD;
&#xD;
          -  Multiple drug allergies&#xD;
&#xD;
          -  Concomitant felbamate use&#xD;
&#xD;
          -  Need for frequent rescue benzodiazepines&#xD;
&#xD;
          -  Concomitant use of vigabatrin&#xD;
&#xD;
          -  All patients diagnosed with congenital short QT syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Maertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seizure, Seizures, Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rufinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

